Drugs / PADNARSERTIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02702492 | Jun 2016 → Jan 2021 | cancer, non-Hodgkin lymphoma | Karyopharm Therapeutics Inc | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04914845 Comparator | Aug 2021 → Jul 2025 | acute myeloid leukemia | University of Colorado, Denver | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2021-04-06 | Antengene Corporation | Regulatory Antengene Appoints Bo Shan as Chief Scientific Officer antengene.com ↗
The NMPA‘s approval of the IND application for ATG-019 indicates the potential of this drug to be applied to Chinese patients. |
| 2020-01-03 | Antengene Corporation | Regulatory News Flash! The PAK4/NAMPT Dual Target Oral Inhibitor, ATG-019, Passed the Review of Investigational New Drug (IND) by Taiwan, China antengene.com ↗ |
| 2018-03-19 | Karyopharm Therapeutics Inc | Results Karyopharm to Present Preclinical Data at the American Association for Cancer Research 2018 Annual Meeting karyopharm.com ↗
Mpilla et al. demonstrate that PAK4-NAMPT dual inhibition with KPT-9274 has activity in preclinical models of resistant pancreatic neuroendocrine tumors. |
| 2017-09-08 | Karyopharm Therapeutics Inc | Results Karyopharm Announces Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting karyopharm.com ↗
These study findings indicate that in patients whose disease has progressed despite most available therapies, KPT-9274 can induce tumor shrinkage and disease stabilization. |
All press releases naming this drug 8 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PADNARSERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297467 ↗ |
| Known as | KPT-9274 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04914845 ↗ |
| Known as | Pak4-in-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297467 ↗ |
| Action | Inhibit | “dual inhibitor of PAK4 and NAMPT” NCT02702492 ↗ |
| Modality | Small molecule | “KPT-9274 is a first-in-class orally bioavailable, non-competitive, small molecule” NCT04914845 ↗ |
| Route | Oral | “oral KPT-9274” NCT02702492 ↗ |
| Target | NAMPT | “dual inhibitor of PAK4 and NAMPT” NCT02702492 ↗ |
| Target | PAK4 | “dual inhibitor of PAK4 and NAMPT” NCT02702492 ↗ |